PRKAB2

Across TCGA pan-cancer cohorts, PRKAB2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PRKAB2 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PRKAB2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PRKAB2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where PRKAB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	III,IV	0.946	0.358	.006	12	view →
LUAD	OS	Tertile	II,III,IV	0.422	0.764	.024	8	view →
CCRCC	OS	Median	All	1.000	0.674	.009	2	view →
HNSC	DFS	Median	III,IV	1.000	0.939	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PRKAB2–PDAC (DFS)

Open the PDAC breakdown →